Clinical Trial Update: Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B [Phase 2]

View source ↗

Summary

Pfizer's PF-06838435 is in a Phase 2 long-term safety and efficacy study with a dose-escalation substudy in people with Hemophilia B; the trial is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• PF-06838435

Snippet

Sponsor: Pfizer | Conditions: Hemophilia B | Phase 2 | Status: ACTIVE_NOT_RECRUITING